Committee on Infectious Diseases,Sean T O'Leary,James D Campbell,Monica I Ardura,Kristina A Bryant,Mary T Caserta,Claudia Espinosa,Robert W Frenck,C Mary Healy,Chandy C John,Athena P Kourtis,Aaron Milstone,Angela Myers,Pia Pannaraj,Adam J Ratner,Annika M Hofstetter,Juan D Chaparro,Jeremy J Michel,David W Kimberlin,Ritu Banerjee,Elizabeth D Barnett,Ruth Lynfield,Mark H Sawyer,Michelle Barton-Forbes,Cristina V Cardemil,Karen M Farizo,Lisa M Kafer,Denee Moore,Chinedu Okeke,Chris Prestel,Manisha Patel,Jeffrey R Starke,Jennifer Thompson,Juan Pablo Torres,Melinda Wharton,Charles R Woods,Gillian Gibbs

Abstract:This statement updates the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccines and antiviral medications in the prevention and treatment of influenza in children during the 2024-2025 influenza season. A detailed review of the evidence supporting these recommendations is published in the accompanying technical report (www.pediatrics.org/cgi/doi/10.1542/peds.2024-068508). The American Academy of Pediatrics recommends annual influenza vaccination of all children without medical contraindications starting at 6 months of age. Children are at risk for hospitalization and death from influenza. Influenza vaccination is an important strategy for protecting children and the broader community as well as reducing the overall burden of respiratory illnesses when other viruses are cocirculating. Any licensed influenza vaccine appropriate for age and health status can be administered, ideally as soon as possible in the season, without preference for one product or formulation over another. All licensed influenza vaccines for use in the United States are trivalent for the 2024-2025 influenza season. Antiviral treatment of influenza is recommended for children with suspected (eg, influenza-like illness [fever with either cough or sore throat]) or confirmed influenza who are hospitalized or have severe or progressive disease or have underlying conditions that increase their risk of complications of influenza, regardless of duration of illness. Antiviral treatment should be initiated as soon as possible. Antiviral treatment may be considered in the outpatient setting for symptomatic children who are not at high risk for influenza complications with suspected or confirmed influenza disease, if treatment can be initiated within 48 hours of illness onset. Antiviral treatment may also be considered for children with suspected or confirmed influenza disease whose siblings or household contacts either are younger than 6 months or have a high-risk condition that predisposes them to complications of influenza. Antiviral chemoprophylaxis is recommended for the prevention of influenza virus infection as an adjunct to vaccination in certain individuals, especially exposed children who are asymptomatic and are at high risk for influenza complications but have not yet been immunized or those who are not expected to mount an effective immune response.

Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): Recommended Immunization Schedule (2023) and Update on Immunization for Children Aged 0 Through 18 Years

Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP) Recommended Immunization Schedule (2018-19) and Update on Immunization for Children Aged 0 Through 18 Years

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2024

June 2024 ACIP Meeting Update: Influenza, COVID-19, RSV, and Other Vaccines

Update on Available Vaccines in India: Report of the APPA VU 2010: I

February 2024 ACIP Meeting Update: Meningococcal, RSV, COVID-19, and Other Vaccines

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024

Indian Academy of Pediatrics Revised (2021) Guidelines on Prevention and Treatment of Vitamin D Deficiency and Rickets

Immunization schedule of the Pediatric Spanish Association: 2022 recommendations

Recommendations for Prevention and Control of Influenza in Children, 2024-2025: Policy Statement

Recommendations for Adult Immunization by the Korean Society of Infectious Diseases, 2023: Minor Revisions to the 3rd Edition

Routine Childhood Vaccines Given From 1 through 18 Years of Age

Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025

IAP Guidelines on Rickettsial Diseases in Children

Developments and Trends of Immunization in India: A Narrative Review

Regional differences in pediatric pneumococcal vaccine schedules for Indigenous children in Canada: an environmental scan

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India

Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

Poliomyelitis prevention: recommendations for use of inactivated poliovirus vaccine and live oral poliovirus vaccine. American Academy of Pediatrics Committee on Infectious Diseases

50 years of immunization in India: progress and future

Expert panel opinion on adult pneumococcal vaccination in the post-COVID era (NAP- EXPO Recommendations-2024)